{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:42:47Z","timestamp":1792222967807,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.aohep.2026.102250","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:27:22Z","timestamp":1788017242000},"page":"102250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world hepatocellular carcinoma management and guideline adherence in the Netherlands: A 5-year multicentre prospective cohort study"],"prefix":"10.1016","volume":"32","author":[{"given":"Coosje A.M.","family":"Verhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1454-2651","authenticated-orcid":false,"given":"Jochem M.","family":"Grossouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"de Bruijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"van der Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-3078","authenticated-orcid":false,"given":"Jeffrey P.B.M.","family":"Braak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik J.H.","family":"Hoogwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-689X","authenticated-orcid":false,"given":"Simeon J.S.","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W.","family":"Nijkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0290-0381","authenticated-orcid":false,"given":"Merve","family":"Rousian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam E.","family":"van der Meeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4893","authenticated-orcid":false,"given":"Wojciech G.","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"den Hoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto M.","family":"van Delden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bart","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-291X","authenticated-orcid":false,"given":"Mark C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minneke J.","family":"Coenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102250_bib0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102250_bib0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0005","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102250_bib0006","first-page":"291","article-title":"Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and inuence on survival rate","volume":"22","author":"Radu","year":"2013","journal-title":"J Gastrointest Liver Dis"},{"issue":"1","key":"10.1016\/j.aohep.2026.102250_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5604\/16652681.1184233","article-title":"Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm","volume":"15","author":"Richani","year":"2016","journal-title":"Ann Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102250_bib0008","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/liv.13107","article-title":"The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?","volume":"36","author":"Kim","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.dld.2014.02.012","article-title":"Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna liver oncology group","volume":"46","author":"Leoni","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fon.12.183","article-title":"Adherence to American association for the study of liver diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study","volume":"9","author":"Borzio","year":"2013","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102250_bib0011","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00270-021-02810-8","article-title":"Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis","volume":"44","author":"Matsumoto","year":"2021","journal-title":"Cardiovasc Interv Radiol"},{"issue":"9","key":"10.1016\/j.aohep.2026.102250_bib0012","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2026.102250_bib0013","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/liv.13888","article-title":"Multimodality treatment of hepatocellular carcinoma: how field practice complies with international recommendations","volume":"38","author":"Sangiovanni","year":"2018","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.aohep.2026.102250_bib0014","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MEG.0000000000001049","article-title":"Adherence to Barcelona clinic liver cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina","volume":"30","author":"Pi\u00f1ero","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2026.102250_bib0015","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/hep.29668","article-title":"Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice","volume":"67","author":"Giannini","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2026.102250_bib0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0017","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.21037\/jgo-22-833","article-title":"Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications?","volume":"13","author":"Barros","year":"2022","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0018","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5152\/dir.2020.19615","article-title":"TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis","volume":"26","author":"Liu","year":"2020","journal-title":"Diagn Interv Radiol"},{"issue":"20","key":"10.1016\/j.aohep.2026.102250_bib0019","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aohep.2026.102250_bib0020","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102250_bib0021","series-title":"Atezolizumab en bevacizumab als eerstelijnsbehandeling bij gevorderd of gemetastaseerd hepatocellulair carcinoom","author":"Bom","year":"2020"},{"key":"10.1016\/j.aohep.2026.102250_bib0022","unstructured":"Specialisten F.M. Dutch guidelines for hepatocellulair carcinoma. Internet. Federatie Medisch Specialisten. Updated 01-01-2024. Accessed 03-07-2025, 2025.https:\/\/richtlijnendatabase.nl\/richtlijn\/hepatocellulair_carcinoom_2023\/startpagina_hepatocellulair_carcinoom_2023.html"},{"issue":"7","key":"10.1016\/j.aohep.2026.102250_bib0023","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00259-024-06630-z","article-title":"Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial)","volume":"51","author":"Hendriks","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.aohep.2026.102250_bib0024","unstructured":"Individualized dosimetry for holmium-166-radioembolization in patients with unresectable hepatocellular carcinoma; a multi-center, interventional, non-randomized, non-comparative, open label, early phase II study. National library of medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05114148"},{"key":"10.1016\/j.aohep.2026.102250_bib0025","unstructured":"Oncology DSfM. Dutch society for medical oncology - comittee BOM. Accessed November 25, 2025, https:\/\/www.nvmo.org\/bom\/"},{"key":"10.1016\/j.aohep.2026.102250_bib0026","unstructured":"BOM Comissie DSfMO. Over de adviezen, PASKWIL-criteria. https:\/\/www.nvmo.org\/over-de-adviezen\/"},{"key":"10.1016\/j.aohep.2026.102250_bib0027","article-title":"Assessment of new oncological drugs","author":"Wymenga","year":"2022","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00432-013-1528-8","article-title":"Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis","volume":"140","author":"Gu","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.aohep.2026.102250_bib0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/CMAR.S152707","article-title":"Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona clinic liver cancer stages","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.aohep.2026.102250_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT","volume":"61","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2026.102250_bib0031","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/liv.13242","article-title":"Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma","volume":"37","author":"Pecorelli","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2026.102250_bib0032","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2026.102250_bib0033","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.aohep.2026.102250_bib0034","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MEG.0000000000000527","article-title":"Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands","volume":"28","author":"Van Meer","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0035","doi-asserted-by":"crossref","first-page":"212","DOI":"10.15403\/jgld-5414","article-title":"The staging of newly diagnosed hepatocellular carcinoma in Romania. A national multicentric study","volume":"33","author":"Cr\u0103ciun","year":"2024","journal-title":"J Gastrointest Liver Dis"},{"issue":"7","key":"10.1016\/j.aohep.2026.102250_bib0036","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1111\/liv.12764","article-title":"Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?","volume":"35","author":"Edenvik","year":"2015","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2026.102250_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35066","article-title":"Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system","volume":"7","author":"Yilma","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.aohep.2026.102250_bib0038","first-page":"299","article-title":"Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy","volume":"72","author":"Eskens","year":"2014","journal-title":"Neth J Med"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0039","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/14574969231220179","article-title":"Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: treatment and survival differences in a nationwide cohort","volume":"113","author":"Engstrand","year":"2024","journal-title":"Scand J Surg"},{"issue":"2","key":"10.1016\/j.aohep.2026.102250_bib0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4254\/wjh.v14.i2.354","article-title":"Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?","volume":"14","author":"Fassio","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.aohep.2026.102250_bib0041","doi-asserted-by":"crossref","DOI":"10.1017\/dmp.2024.176","article-title":"Impact of COVID-19 on incidence, treatment, and survival of patients with hepatocellular carcinoma in the Netherlands","volume":"18","author":"Furumaya","year":"2024","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.aohep.2026.102250_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2020.101304","article-title":"Immediate impact of COVID-19 on transplant activity in the Netherlands","volume":"61","author":"de Vries","year":"2020","journal-title":"Transpl Immunol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:29:56Z","timestamp":1792222196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1665268126000700"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102250","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world hepatocellular carcinoma management and guideline adherence in the Netherlands: A 5-year multicentre prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102250"}}